Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies (Q38197031)

30 August 2017

1 reference

title

Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies (English)

1 reference

30 August 2017

Mark Linch

1

0 references

author name string

Aisha B Miah

2

1 reference

30 August 2017

Khin Thway

3

1 reference

30 August 2017

Ian R Judson

4

1 reference

30 August 2017

Charlotte Benson

5

1 reference

30 August 2017

language of work or name

English

0 references

publication date

18 March 2014

1 reference

Nature Reviews Clinical Oncology

30 August 2017

1 reference

30 August 2017

11

1 reference

30 August 2017

187-202

1 reference

30 August 2017

4

1 reference

Soft-tissue sarcomas in adults

30 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

The diversity of soft tissue tumours with EWSR1 gene rearrangements: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Tumors with EWSR1-CREB1 and EWSR1-ATF1 fusions: the current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Paediatric and adolescent alveolar soft part sarcoma: A joint series from European cooperative groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Cediranib for metastatic alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Recent developments in uterine mesenchymal neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Differential sensitivity of liposarcoma subtypes to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Phase II trial of paclitaxel in patients with soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Translocation t(7;19)(q22;q13)−a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Solitary fibrous tumors of the soft tissues: review of the imaging and clinical features with histopathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Sunitinib malate in solitary fibrous tumor (SFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

The nuts and bolts of AGC protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Oncolytic viruses as therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

SRC signaling is crucial in the growth of synovial sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

MET signalling: principles and functions in development, organ regeneration and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Expression and clinical relevance of MET and ALK in Ewing sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Multiple levels of cyclin specificity in cell-cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Targeting RAS and PI3K in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Transforming growth factor-alpha prevents detachment-induced inhibition of c-Src kinase activity, Bcl-XL down-regulation, and apoptosis of intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A phase II trial with rosiglitazone in liposarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Future directions for immunotherapeutic intervention against sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Immune-based therapies for sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma G

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Molecular biology of soft-tissue sarcomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Neoadjuvant treatment of soft tissue sarcoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Mode of action of trabectedin in myxoid liposarcomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Synovial sarcoma. Uniform response of metastases to high dose ifosfamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Gastrointestinal stromal tumours: origin and molecular oncology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Characterization of the 12q13-15 amplicon in soft tissue tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Clinical outcomes of extra-thoracic solitary fibrous tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Response to chemotherapy of solitary fibrous tumour: A retrospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Immunohistochemical localization of endothelial cell markers in solitary fibrous tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Phase II Trials of Interferons-α and -β in Advanced Sarcomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Bevacizumab for recurrent hemangioendothelioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.26

Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up

31 March 2020

1 reference

12 December 2020

Update on imatinib for gastrointestinal stromal tumors: duration of treatment

1 reference

12 December 2020

The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.

1 reference

12 December 2020

Activity of angiogenesis inhibitors in metastatic epithelioid hemangioendothelioma: a case report

1 reference

12 December 2020

Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data

1 reference

12 December 2020

The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit

1 reference

12 December 2020

The microtubule-affecting drug paclitaxel has antiangiogenic activity

1 reference

12 December 2020

10.1038/NRCLINONC.2014.26

Identifiers

DOI

1 reference

30 August 2017

1 reference